Roche Scores Small Win in Lung Cancer, but Overall Victory Will be Harder

Dow Jones07-02

0722 GMT - Roche Holding's positive results in a lung cancer trial give the Swiss drugmaker a small win, but it would be premature to claim overall victory, Jefferies analysts say in a research note. Roche's divarasib met the goals in a late-stage clinical trial for a type of lung cancer in patients already treated, but might struggle in the bigger population of previously untreated patients, the analysts say. The study results mean Roche can target a revenue opportunity of between 1 billion and 2 billion Swiss francs, according to Jefferies. "The bigger opportunity would be in the [first-line setting], but that is a whole different ballgame," the analysts add. Success for divarasib in the first-line setting for this type of lung cancer would open up a revenue opportunity of 3 billion to 5 billion francs, Jefferies says. Shares rise 1%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 02, 2026 03:23 ET (07:23 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648243572?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 15:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648243572","market":"nz","top_or_hot":-1,"title":"Roche Scores Small Win in Lung Cancer, but Overall Victory Will be Harder","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0722 GMT - Roche Holding's positive results in a lung cancer trial give the Swiss drugmaker a small win, but it would be premature to claim overall victory, Jefferies analysts say in a research note. Roche's divarasib met the goals in a late-stage clinical trial for a type of lung cancer in patients already treated, but might struggle in the bigger population of previously untreated patients, the analysts say. The study results mean Roche can target a revenue opportunity of between 1 billion and 2 billion Swiss francs, according to Jefferies. \"The bigger opportunity would be in the [first-line setting], but that is a whole different ballgame,\" the analysts add. Success for divarasib in the first-line setting for this type of lung cancer would open up a revenue opportunity of 3 billion to 5 billion francs, Jefferies says. Shares rise 1%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 02, 2026 03:23 ET (07:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche Scores Small Win in Lung Cancer, but Overall Victory Will be Harder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche Scores Small Win in Lung Cancer, but Overall Victory Will be Harder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-02 15:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0722 GMT - Roche Holding's positive results in a lung cancer trial give the Swiss drugmaker a small win, but it would be premature to claim overall victory, Jefferies analysts say in a research note. Roche's divarasib met the goals in a late-stage clinical trial for a type of lung cancer in patients already treated, but might struggle in the bigger population of previously untreated patients, the analysts say. The study results mean Roche can target a revenue opportunity of between 1 billion and 2 billion Swiss francs, according to Jefferies. \"The bigger opportunity would be in the [first-line setting], but that is a whole different ballgame,\" the analysts add. Success for divarasib in the first-line setting for this type of lung cancer would open up a revenue opportunity of 3 billion to 5 billion francs, Jefferies says. Shares rise 1%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 02, 2026 03:23 ET (07:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHHBY","symbol_name":"罗氏控股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2648243572","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648243572","pubTimestamp":1782976980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0722 GMT - Roche Holding's positive results in a lung cancer trial give the Swiss drugmaker a small win, but it would be premature to claim overall victory, Jefferies analysts say in a research note. Roche's divarasib met the goals in a late-stage clinical trial for a type of lung cancer in patients already treated, but might struggle in the bigger population of previously untreated patients, the analysts say. The study results mean Roche can target a revenue opportunity of between 1 billion and 2 billion Swiss francs, according to Jefferies. \"The bigger opportunity would be in the [first-line setting], but that is a whole different ballgame,\" the analysts add. Success for divarasib in the first-line setting for this type of lung cancer would open up a revenue opportunity of 3 billion to 5 billion francs, Jefferies says. Shares rise 1%.  Dow Jones NewswiresJuly 02, 2026 03:23 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RHHBY":"罗氏控股","BK4007":"制药","03165":"华夏欧优股对冲"},"translate_title":"罗氏肺癌小胜，但全面胜利将更加艰难","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.9,"03165":0.6},"content_text":"0722 GMT - Roche Holding's positive results in a lung cancer trial give the Swiss drugmaker a small win, but it would be premature to claim overall victory, Jefferies analysts say in a research note. Roche's divarasib met the goals in a late-stage clinical trial for a type of lung cancer in patients already treated, but might struggle in the bigger population of previously untreated patients, the analysts say. The study results mean Roche can target a revenue opportunity of between 1 billion and 2 billion Swiss francs, according to Jefferies. \"The bigger opportunity would be in the [first-line setting], but that is a whole different ballgame,\" the analysts add. Success for divarasib in the first-line setting for this type of lung cancer would open up a revenue opportunity of 3 billion to 5 billion francs, Jefferies says. Shares rise 1%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 02, 2026 03:23 ET (07:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648243572","isCrawlerRequest":true}